Skip to content

The effective dose of remimazolam combined with sufentanil in painless oocyte retrieval

The effective dose of remimazolam combined with sufentanil in painless oocyte retrieval

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400082576
Enrollment
Unknown
Registered
2024-04-01
Start date
2024-04-01
Completion date
Unknown
Last updated
2024-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Painless oocyte retrieval

Interventions

Remimazolam goup:All patients received intravenous sufentanil 0.1µg/kg. After 2 min, remimazolam was administered intravenously. The initial remimazolam dose was set at 0.2mg/kg and varied by 0.02mg/k

Sponsors

Zhejiang Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1.Patients who undergoing painless oocyte retrieval 2.Body mass index (BMI) of 18.5-27.9 kg/m2 3. American Society of Anesthesiologists (ASA) physical status I–II 4.Procedure duration no more than 10 min

Exclusion criteria

Exclusion criteria: 1. Allergy to benzodiazepines and opioids 2. Diagnosed with severe dysfunction of vital organs 3. Having any mental illness or taking psychotropic drugs 4.Unwilling to participate in the study

Design outcomes

Primary

MeasureTime frame
Positive or negative reaction;Remimazolam dose;

Secondary

MeasureTime frame
Total surgery time;Adverse events;Time to loss of consciousness;

Countries

China

Contacts

Public ContactYanfei Lu

Zhejiang Provincial People's Hospital

1192508536@qq.com+86 189 7094 0268

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026